Bioatla Inc BCAB

$1.69 -0.05 (-2.59%)

Valuation

Market cap
2,891,000
Revenue TTM
$2,000,000
Net income TTM
$-59,610,000
PE ratio
0.00
Forward PE
—
Profit margin
-2,980.50%
Debt to equity
0.00

Trading

Volume
130,200
Avg volume
84,918
Day's range
$1.31 – $2.13
Shares out
1,666,000
Stochastic %K
14%
Beta
0.78
Analysts
Hold
Price target
$10.00

Price

Company profile

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedot...

Show more

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 558 0708
Website
https://www.bioatla.com
Address
11085 Torreyana Road, San Diego, United States

Latest news

Stocktwits

LuckyEnzo Oct 1, 5:47 PM
@EquivalentExchange is on an absolute tear recently🔥the plays just keep getting better! If you’re not following yet you’re missing out. $PETZ $BCAB $MNDR priorities
0 replies
BiotechValues Oct 1, 3:19 PM
$BCAB if they do a deal by EOY, as the filing/new website suggests, probably 5-10x upside from here depending on how much they get for Oz-V. $2M market cap and last year were supposed to get $40M upfront for 35% of the drug, so over $100M valuation for Oz-V alone
1 replies
Mugu Sep 30, 12:15 PM
$BCAB could have been a contender
0 replies
Digfog Sep 30, 1:35 AM
$BCAB now that sievers left it’s down to Jay and a junior accountant with a CFO title. Next up is a sale of desks and computer equipment in front of of their office…
1 replies
BiotechValues Sep 29, 10:10 PM
$BCAB key words "In view of the ongoing strategic process...the Board approved a partial reinstatement of the retention bonus program"
1 replies
BiotechValues Sep 29, 9:47 PM
$BCAB Sounds like they plan to have a deal done by EOY and that's why they are resurrecting the bonuses.
0 replies
BiotechValues Sep 29, 9:27 PM
$BCAB something brewing. Obviously it's INVERSAGEN AI trying to raise funds to license BCAB asset(s)
0 replies
LabPsycho Sep 26, 2:02 PM
$BCAB @BiotechValues Remember the good ole days when BioGrifters of failed biotech companies would just use the go-to multilevel scam of switching to crypto (when it was hot) to try to salvage their faux biotech company that was 90-99% off its historic highs? Now, I guess the buzz word du jour - i mean, du an, is "A.I." so I should probably update my fictitious (but hopefully for not much longer) book: The BioGrifter's Wealth Transfer Playbook to reflect the "there's a new scam in town". Let's use A.I. to do some pretend math to convince more saps that our drug that either does not work or is not competitive actually could work.
2 replies